Back to mobile site

Cantor Fitzgerald: 'We now expect apitegromab to have near complete market share'

March 19, 2026 2:11 PM EDT Send to a Friend
Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating and {REMOVEPT} price target on Scholar Rock (NASDAQ: SRRK).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login